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Background. Historically, Nigeria has experienced large bacterial meningitis outbreaks with high mortality in children. 
Streptococcus pneumoniae (pneumococcus), Neisseria meningitidis (meningococcus), and Haemophilus influenzae are major causes 
of this invasive disease. In collaboration with the World Health Organization, we conducted longitudinal surveillance in sentinel 
hospitals within Nigeria to establish the burden of pediatric bacterial meningitis (PBM).
Methods. From 2010 to 2016, cerebrospinal fluid was collected from children <5 years of age, admitted to 5 sentinel hospitals in 
5 Nigerian states. Microbiological and latex agglutination techniques were performed to detect the presence of pneumococcus, me-
ningococcus, and H. influenzae. Species-specific polymerase chain reaction and serotyping/grouping were conducted to determine 
specific causative agents of PBM.
Results. A total of 5134 children with suspected meningitis were enrolled at the participating hospitals; of these 153 (2.9%) were 
confirmed PBM cases. The mortality rate for those infected was 15.0% (23/153). The dominant pathogen was pneumococcus (46.4%: 
71/153) followed by meningococcus (34.6%: 53/153) and H. influenzae (19.0%: 29/153). Nearly half the pneumococcal meningitis 
cases successfully serotyped (46.4%: 13/28) were caused by serotypes that are included in the 10-valent pneumococcal conjugate vac-
cine. The most prevalent meningococcal and H. influenzae strains were serogroup W and serotype b, respectively.
Conclusions. Vaccine-type bacterial meningitis continues to be common among children <5 years in Nigeria. Challenges with 
vaccine introduction and coverage may explain some of these finding. Continued surveillance is needed to determine the distribu-
tion of serotypes/groups of meningeal pathogens across Nigeria and help inform and sustain vaccination policies in the country.
Keywords.  pediatric; meningitis; Nigeria; pneumococcus; meningococcus.
Acute bacterial meningitis is a much-dreaded infectious disease in 
children and a major cause of morbidity and mortality [1, 2]. The 
incidence and case-fatality rates for this invasive bacterial disease 
vary by region, country, causative-agent, and age-group affected, 
but without adequate treatment, fatalities can be as high as 70% [1, 
3]. The African meningitis belt is the most significantly affected 
area worldwide, with an estimated 400 million people at-risk an-
nually. Bacterial meningitis epidemics have occurred frequently 
across this region for over a century: one of the largest occurred 
in Nigeria during 1996, with over 109 000 cases and 11 000 deaths 
[4]. Subsequently, there have been several major outbreaks within 
Nigeria, over wide geographical areas, most notably in 2009 and 
2015 [4, 5]. In December 2016, the Nigeria Centre for Disease 
Control (NCDC) received reports of a meningitis outbreak. By 
May 2017, there were 13  420 suspected cases and 1069 deaths 
(8%), of which 47% were children in the 5–14 year age group [6].
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The leading causes of bacterial meningitis are Neisseria 
meningitidis (meningococcus), Streptococcus pneumoniae 
(pneumococcus), and Haemophilus influenzae; which are 
usually carried asymptomatically in the nasopharynx and 
transmitted through respiratory droplets [1]. Normally, the 
pathogen responsible for epidemics is the Neisseria spe-
cies, whereas pneumococcus and H.  influenzae are endemic 
throughout the year [4, 7, 8]. In 2008, the World Health 
Organization (WHO) established the Global Invasive Bacterial-
Vaccine Preventable Diseases (IB-VPD) network building on 
regional surveillance networks. This global surveillance net-
work encompasses 100 sentinel hospital laboratories, aiming 
to estimate the burden of bacterial meningitis and characterize 
circulating bacterium within member countries [2, 9]. As part 
of this, the Medical Research Council Unit The Gambia at the 
London School of Hygiene and Tropical Medicine (MRCG 
at LSHTM), a WHO  Collaborating Center for New Vaccines 
Surveillance (WHO CC NVs), provides laboratory support for 
pediatric bacterial meningitis (PBM) surveillance in 10 coun-
tries across West Africa, including Nigeria.
Nigeria is the most populous country within Africa, with 
an estimated 193 million people living in 36 states [10]. The 
national human immunodeficiency virus (HIV) prevalence 
among adults aged 15–49 year in Nigeria is 1.4%; however, this 
varies between states with 5.6% estimated in the southern Akwa 
Ibom State and 0.3% in the northwestern Katsina State [11, 12]. 
In 2012, the Nigerian Expanded Program on Immunization 
(EPI) replaced the diphtheria-tetanus-pertussis and hepatitis B 
vaccines with a pentavalent vaccine that included H. influenzae 
type b (Hib) and underwent a phased introduction [13]. 
Additionally, meningococcal A conjugate vaccine (MenAfriVac) 
campaigns were carried out from 2011 to 2014 in 19 states in 
Northern Nigeria. The 2017 outbreak was caused by meningo-
coccal serogroup C; thus, a vaccine with longevity against this 
strain is required [14]. A phased introduction of the 10-valent 
pneumococcal conjugate vaccine (PCV10) throughout Nigeria, 
targeting 10 invasive pneumococcal serotypes, commenced in 
December 2014 and concluded in October 2016. However, the 
2017 WHO and United Nations Children’s Fund (UNICEF) na-
tional immunization coverage estimates suggest that coverage 
rates for children who received 3 doses of PCV10 and Hib-
containing vaccines remain low, at 36% and 42%, respectively 
[15]. As part of the IB-VPD network, longitudinal surveillance 
was established in 2010 within 5 sentinel hospitals in 5 Nigerian 
states. We have conducted analysis to estimate the prevalence of 
bacterial meningitis in children <5 years of age and determine 
the distribution of the causative pathogens from 2010 to 2016.
METHODS
Surveillance Sites
Surveillance of children <5 years admitted to sentinel hospitals 
with suspected meningitis, was carried out for 7  years. PBM 
surveillance started in Lagos University Teaching Hospital 
(Lagos State) in 2010, followed by University of Nigeria 
Teaching Hospital (Enugu State) in 2011. In the following 
year, 2 more sites were included: Abubakar Tafawa Balewa 
University Teaching Hospital (Bauchi State) and University 
of Ilorin Teaching Hospital (Kwara State). Finally, in 2013, 
University of Benin Teaching Hospital (Edo State) joined sur-
veillance. Therefore, surveillance was conducted in 5 states with 
a combined estimated population of approximately 32 million 
people.
Case Enrollment
Hospitalized children aged 0–59  months (<5  years) with 
features of suspected meningitis: rapid onset of fever with 
axillary or rectal temperatures of >38°C and >38.5°C, 
combined with any of the following symptoms: impaired 
consciousness, meningismus (stiff neck), photophobia, 
bulging fontanelle (infants), and convulsions were enrolled 
in the surveillance [16]. A  lumbar puncture (LP) was 
performed for routine diagnostic tests, and cerebrospinal 
fluid (CSF) was collected.
CSF Analysis
CSF samples were processed following the WHO standard op-
erating procedure [16]. An aliquot of CSF was centrifuged, and 
the deposit inoculated onto Columbia blood and chocolate agar 
plates and incubated overnight. Isolates of the target pathogens 
were identified using the optochin test (5  μg optochin disk; 
Oxoid, Basingstoke, UK) for pneumococcus and analytical pro-
file index (API NH; Biomerieux, Basingstoke, UK) for meningo-
coccus and H. influenzae. The remaining centrifuged pellet was 
used to prepare smears for Gram staining. Using the supernatant, 
latex agglutination was performed with the Pastorex meningitis 
kit (Biorad, Watford, UK), for the detection of pneumococcus, 
Hib and meningococcus groups A, B, C, Y, and W antigens. 
When possible, CSF was used to detect the presence of pneumo-
coccus using the BINAX® NOW kit (Alere Inc., Waltham, MA, 
USA). A  white blood cell (WBC) count was conducted along 
with CSF protein and glucose analysis using trichloroacetic acid 
turbidimetric and glucose oxidase methods [17, 18].
Molecular Analysis
CSF samples were transported to the MRCG at LSHTM ac-
cording to International Air Transport Association (IATA) 
regulations [19]. Species-specific quantitative polymerase 
chain reaction (qPCR) assays for detection of pneumococcus, 
meningococcus, and H.  influenzae were performed, using the 
autolysin gene (lytA), Cu, Zn superoxide dismutase gene (sodC) 
and protein D encoding gene (hpd), respectively, as described 
elsewhere [20]. For amplification, samples were heated at 95°C 
for 10 minutes, followed by 45 cycles of 95°C for 15 seconds 
and 60°C for 1 minute. Cycle threshold (CT) values of ≤36 were 
considered positive results.
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Serotyping and Serogrouping
Meningococcus and H.  influenzae serogrouping/typing was 
conducted using direct qPCR. Meningococcal gene targets 
were: sacB, synD, synE, synG, xcbB, synF for serogroups A, B, 
C, W, X, and Y, respectively. Additionally, for H. influenzae gene 
targets included acsB, bcsB, ccsD, dscE, ecsH, bexD for serotypes 
Hia, Hib, Hic, Hid, Hie, and Hif, respectively. CT values of ≤32 
were considered positive [21]. For pneumococcus, nucleic acid 
extraction using Qiagen DNA Mini-kit was performed. Purified 
DNA underwent sequential triplex qPCR for detection of 21 
capsular serotypes as described elsewhere [22]. Nontypeable 
pneumococci, with CT values ≤32 by qPCR, were further 
subjected to conventional multiplex serotyping PCR assays.
Statistical Analysis
Data were collected at the sentinel hospitals using a standardized 
WHO Regional Office for Africa (Afro) PBM network case 
report form. Information recorded included, patient demo-
graphics, clinical symptoms, vaccination history, laboratory in-
formation (CSF microscopy, bacteriological tests, genotyping), 
and outcome at discharge. Data were subsequently put into a 
WHO Epi Info-based customized new-vaccine surveillance data 
module. Data cleaning and analysis were first performed at the 
sentinel site level before being sent to the national and regional 
WHO data managers. At the national level, data from sites were 
merged, cleaned, analyzed, and interpreted. Merged data were 
then sent to WHO Afro data managers, and feedback was pro-
vided to sites every 3–6 months. WHO Afro also sent regional 
data to WHO Global data managers. For presentation here, data 
were analyzed using GraphPad Prism 8.1.1; percentages, pro-
portion, means, and standard deviations were calculated as ap-
propriate and presented as prose, tables, and figures.
Ethical approval was not a requirement in Nigeria for routine 
meningitis surveillance including drug susceptibility testing 
of collected isolates as this is approved within the routine di-
agnostic algorithm at the Ministry of Health. However, in-
formed consent was sought from caregivers of the surveillance 
participants. Additionally, the surveillance received overarching 
ethical approval (SCC1188) by the joint MRC/The Gambia 
Government ethics board that allowed the analysis of collected 
West African isolates at MRC Unit, The Gambia.
RESULTS
Demographic and Clinical Characteristics
Details of the demographic characteristics of the children 
enrolled in surveillance are shown in Table 1. A total of 5134 
children <5  years of age with suspected bacterial meningitis 
were enrolled at the sentinel hospitals from 2010 to 2016. Of 
these, 5008 (97.5%: 5008/5134) children had CSF samples 
collected, which then underwent diagnostic testing. Overall, 
57.8% (2969/5134) of patients were male and the median age 
Table 1.  Summary of Demographic Characteristics of Study Population
Total Bauchia Lagosb Edoc Kwarad Enugue
Characteristic Category n (%) n (%) n (%) n (%) n (%) n (%)
Age 0–11 m 3014 (58.7) 230 (32.4) 1473 (72.3) 588 (67.1) 222 (37.1) 501 (54.9)
12–23 m 798 (15.5) 120 (16.9) 222 (10.9) 120 (13.7) 127 (21.2) 209 (22.9)
24–59 m 1234 (24.0) 358 (50.4) 264 (13.0) 164 (18.7) 247 (41.3) 201 (22.0)
Unknown 88 (1.7) 2 (0.3) 79 (3.9) 4 (0.5) 2 (0.3) 1 (0.1)
Sex Female 2147 (41.8) 300 (42.3) 843 (41.4) 356 (40.6) 269 (45.0) 379 (41.6)
Male 2969 (57.8) 410 (57.7) 1181 (57.9) 516 (58.9) 329 (55.0) 533 (58.4)
Unknown 18 (0.4) 0 (0.0) 14 (0.7) 4 (0.5) 0 (0.0) 0 (0.0)
Antibiotic before admission Yes 743 (14.5) 62 (8.7) 313 (15.4) 24 (2.7) 85 (14.2) 259 (28.4)
No 2972 (57.9) 581 (81.8) 622 (30.5) 834 (95.2) 329 (55.0) 606 (66.4)
Unknown 1419 (27.6) 67 (9.4) 1103 (54.1) 18 (2.1) 184 (30.8) 47 (5.2)
Outcome diagnosis Meningitis 363 (7.1) 107 (15.1) 87 (4.3) 42 (4.8) 22 (3.7) 105 (11.5)
Pneumonia 72 (1.4) 37 (5.2) 11 (0.5) 4 (0.5) 12 (2.0) 8 (0.9)
Septicemia 235 (4.6) 26 (3.7) 101 (5.0) 4 (0.5) 34 (5.7) 70 (7.7)
Other/multiple 1022 (19.9) 301 (42.4) 120 (5.9) 173 (19.7) 255 (42.6) 173 (19.0)
Unknown 3442 (67.0) 239 (33.7) 1719 (84.3) 653 (74.5) 275 (46.0) 556 (61.0)
Outcome Discharged Alive 3107 (60.5) 561 (79.0) 935 (45.9) 308 (35.2) 456 (76.3) 847 (92.9)
Died 278 (5.4) 93 (13.1) 49 (2.4) 52 (5.9) 39 (6.5) 45 (4.9)
Unknown 1749 (34.1) 56 (7.9) 1054 (51.7) 516 (58.9) 103 (17.2) 20 (2.2)
Total no. of suspected cases recruitedf 5134 (100.0) 710 (13.8) 2038 (39.7) 876 (17.1) 598 (11.6) 912 (17.8)
aAbubakar Tafawa Balewa University Teaching Hospital. 
bLagos University Teaching Hospital.
cUniversity of Benin Teaching Hospital. 
dUniversity of Ilorin Teaching Hospital. 
eUniversity of Nigeria Teaching Hospital.
fSuspected cases include cases that were defined as probable per World Health Organization case definition guidelines [16].
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of patients was 22  months (interquartile range: 1–23). The 
largest proportion of meningitis cases were reported in children 
from the youngest age group, 0–11 months, with 3014 (58.7%: 
3014/5134) suspected cases. Unfortunately, 278 patients with 
suspected meningitis died in hospital resulting in a case fatality 
of 5.4% (278/5134).
The clinical characteristics of the children enrolled are de-
tailed in Table 2. In summary, 75 (2.2%: 75/3338) children 
who presented with clear CSF samples had confirmed bacterial 
meningitis. However, a higher proportion of patients (4.5%: 
75/1667) with turbid, xanthrochromic and blood-stained CSF 
samples had confirmed bacterial meningitis. The percentage of 
patients with PBM increased with WBC count; 1.7% (67/3888) 
of patients with a low WBC count (≤10 cells/mm3) had bacte-
rial meningitis, whereas 3.4% (12/352) and 14.8% (29/196) of 
children with >10 to 100 cells/mm3 and >100 cells/mm3, respec-
tively, were infected. More patients with PBM had high levels 
of protein (>100 mg/dL) in their CSF (9.5%: 42/441) compared 
to those with low protein levels ≤100 mg/dL (2.7%: 81/3010). 
However, more children with CSF glucose levels of ≤40  g/
dL had PBM (4.5%: 57/1279) compared to 2.9% (64/2193) of 
patients with lower glucose levels (>40 g/dL).
There were a total of 153 (3.0%: 153/5134) cases of PBM 
observed at the 5 sentinel hospitals during the surveillance 
period in Nigeria. Pneumococcus was responsible for 71 
cases (46.4%: 71/153) with a mortality rate of 14.1% (10/71). 
Meningococcal meningitis was confirmed in 53 (34.6%:53/153) 
pediatric patients with a case fatality rate of 20.7% (11/53). 
A  total of 29 (19.0%: 29/153) children had meningitis caused 
by H. influenzae, among these 2 patients died; mortality rate of 
3.4% (2/29). The overall mortality rate for confirmed bacterial 
meningitis cases was 15% (23/153).
Distribution of Bacterial Pathogens
The number of suspected PBM cases observed in each of the 
5 sentinel hospitals varied annually with an average of 715.4 
cases per year (Figure 1). In 2013, with 5 sentinel hospitals 
enrolled, the total number of suspected cases peaked at 1204. 
Lagos State had the highest proportion of suspected meningitis 
over the study period (39.7%: 2038/5134) and Kwara State the 
least (11.6%: 598/5134). Additionally, the prevalence of menin-
gitis caused by each of the 3 bacterial pathogens varied annually 
(Figure 2).
The frequency of confirmed meningitis cases observed 
fluctuated between months of the year (Figure 3). Presentation 
of PBM was highest from February to June throughout the sur-
veillance period, and the highest number of cases was recorded 
in April. The prevalence of each causative agent varied from 
month to month. For instance, from February to April, most 
cases were caused by meningococcus 34 (51.5%: 34/66) and 
from May to August the dominant pathogen switched to pneu-
mococcus with 28 (59.6%: 28/47) cases.
Serotype and Serogroup Distribution
Serotype analysis was attempted on 31 (43.7%: 31/71) pneu-
mococcal positive CSF samples, however, 3 samples had a low 
concentration of DNA with CT values of >32 so could not be 
serotyped. Of the 28 isolates that were successfully serotyped, 
a variety of pneumococcal serotypes were responsible for PBM 
from year to year. For instance, the pneumococcal meningitis 
cases in 2011 and 2012 were caused by serotype 23F and 14, re-
spectively, both of which are targeted by the PCV10 vaccine. We 
successfully serotyped 2 cases in 2013, which were caused by 
serotype 23F and 19A, which is a non-PCV10 serotype. In 2014, 
10 pneumococcal meningitis cases were serotyped; of these, 1 
Table 2.  Summary of Clinical Characteristics of Patients in Relation to Causative
Recruited Tested Pneumococcus Meningococcus Haemophilus influenzae
Characteristic  n n (%) n (%) n (%) n (%)
Cerebrospinal fluid appearance Clear 3338 3281 (98.3) 39 (1.2) 18 (0.5) 18 (0.5)
Turbid 418 411 (98.3) 20 (4.9) 18 (4.4) 6 (1.5)
Xanthrochromic 635 624 (98.3) 6 (1.0) 9 (1.4) 1 (0.2)
Blood stained 614 607 (98.9) 4 (0.7) 8 (1.3) 3 (0.5)
Unknown 129 85 (65.9) 2 (2.4) 0 1 (1.2)
White blood cell count (cells/mm3) ≤10 3888 3840 (98.8) 33 (0.9) 20 (0.5) 14 (0.4)
>10 to 100 352 348 (98.3) 4 (1.1) 6 (1.7) 2 (0.6)
>100 196 195 (99.5) 15 (7.7) 11 (5.6) 3 (1.5)
Unknown/not done 698 625 (90.0) 19 (3.0) 16 (2.6) 10 (1.6)
Protein (mg/dL) ≤100 3010 2952 (98.1) 41 (1.4) 20 (0.7) 20 (0.7)
>100 441 432 (98.0) 15 (3.5) 23 (5.3) 4 (0.9)
Unknown/not done 1683 1624 (96.5) 15 (0.9) 10 (0.6) 5 (0.3)
Glucose (g/dL) ≤40 1279 1261 (98.6) 21 (1.7) 23 (1.8) 13 (1.0)
≥40 2193 2146 (97.9) 35 (1.6) 19 (0.9) 10 (0.5)
Unknown/not done 1662 1601 (96.3) 15 (0.9) 11 (0.7) 6 (0.4)
Total no. of suspected cases recruiteda 5134 5008 (97.5) 71 (1.4) 53 (1.1) 29 (0.6)
aSuspected cases include cases that were defined as probable as per World Health Organization case definition guidelines [16].
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case was caused by serotype 4, a PCV10 serotype. However, the 
remaining 9 (90%: 9/10) were caused by pneumococcal strains 
that were nontypeable by PCR and, thus, not covered by the 
current formulations of PCV. The 3 serotyped cases in 2015 
were all caused by PCV10 serotypes, serotype’s 1, 5, and 18C. 
A further 11 cases were serotyped in 2016: 6 cases were caused 
by 4 PCV10 serotypes (4, 6B, 19F, and 23F), 4 cases were caused 
by pneumococci that were nontypeable by PCR, and 1 case was 
caused by serotype 23A, a non-PCV10 pathogen. Overall, half 
(50.0%: 14/28) of the pneumococcal meningitis cases that were 
successfully serotyped were caused by serotypes that are not 
targeted by PCV10 vaccine.
Furthermore, most of the meningococcal meningitis cases 
were reported from 2014 to 2016, with 41 (77.4%: 41/53) 
patients across the 3 years and a peak of 17 cases in 2015. In 
total, 20 (37.7%: 20/53) meningococcal isolates underwent 
serogrouping analysis. Four serogroups were observed within 
the surveillance period, the most prevalent was serogroup 
Figure 1. Distribution of suspected pediatric bacterial meningitis cases from 2010 to 2016 within 5 sentinel hospitals in 5 Nigerian states. A total of 5134 suspected pe-
diatric bacterial meningitis cases were observed at 5 sentinel hospitals: Lagos University Teaching Hospital (Lagos State), University of Nigeria Teaching Hospital (Enugu 
State), Abubakar Tafawa Balewa University Teaching Hospital (Bauchi State), University of Ilorin Teaching Hospital (Kwara State), and University of Benin Teaching Hospital 
(Edo State). Each hospital commenced surveillance at different time points; however, surveillance continued for all hospitals until 2016. The number of suspected cases of 
bacterial meningitis and the number of confirmed cases of meningitis (World Health Organization definitions [16]) varied per hospital. The main causative agents for bacterial 
meningitis were Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae.
Figure 2. Proportion of confirmed pediatric bacterial meningitis cases and the 
pathogens responsible from 2010 to 2016 in 5 Nigerian states. The percentage 
of confirmed bacterial meningitis cases caused by Streptococcus pneumoniae, 
Neisseria meningitidis, and Haemophilus influenzae in children <5 years across 5 
Nigerian states. A dashed black line indicates the total number of cerebrospinal 
fluid samples that were tested each year of surveillance.
Figure 3. Monthly distribution of suspected pediatric bacterial meningitis cases 
for the period 2010 to 2016 within 5 sentinel hospitals across Nigeria. The per-
centage of pediatric bacterial meningitis (PBM) cases seen across 5 hospitals in 5 
Nigerian states, caused by Streptococcus pneumoniae, Neisseria meningitidis, and 
Haemophilus influenzae per month. A black dashed line indicates the total number 
of PBM cases per month throughout the surveillance period.
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W, with 8 cases (40%: 8/20) reported in 2015, followed by a 
nongroupable strain causing 1 case in 2015 and 5 cases in 2016 
(30%: 6/20). Serogroup B meningococcus was responsible for 5 
case, 1 each in 2013 and 2015 and a further 3 in 2016. However, 
serogroup C was identified in 1 case of meningococcal menin-
gitis in 2014.
Finally, of the 29 H.  influenzae positive CSF samples, se-
rotype analysis was successfully performed on 16 (55.2%: 
16/29) of these. The most prevalent serotype was Hib, respon-
sible for 1 case in 2012, 2 cases in 2013, and 8 cases in 2016 
(69%:11/16). Hia caused 3 infections in 2015, and Hic was re-
sponsible for 2 infection in 2015. Interestingly, 2 of the patients 
with H. influenzae meningitis reported receiving at least 1 dose 
of the Hib vaccine, 1 case was caused by serotype Hia, and the 
other was not serotyped.
DISCUSSION
We conducted detailed analysis of longitudinal PBM surveil-
lance data from 5 hospitals in 5 states of Nigeria. We found 
the highest number of suspected bacterial meningitis cases in 
children from the youngest age group and a lower number of 
cases reported in children aged 12–23 months but rising in the 
eldest cohort of children aged 24–59 months (Table 1). This was 
unexpected, as previous studies in The Gambia, Oman, and 
Turkey have shown that the incidence of bacterial meningitis 
decreases with age, due to maturation of the immune response 
[23–25]. The mortality rate of suspected meningitis was 5.4% 
(278/5134). However, when excluding data for patients where 
the outcome at discharge was not recorded (34.1%: 1749/5134), 
the mortality rate increased to 8.2% (278/3385), suggesting that 
suspected meningitis patients were severely unwell. Sequelae 
was only reported for 2% (102/5134) of patients with suspected 
meningitis; however, this prevalence is likely to be higher given 
the large number of patients (62.3%: 3245/5134) without fol-
low-up after discharge.
Diagnosis of acute bacterial meningitis can be difficult in 
sub-Saharan Africa where resources are limited and clinical 
features are similar to malarial infections [26]. Analysis of 
CSF through microbiology culture is the gold standard tech-
nique used to detect PBM; however, studies have found low 
bacterial recovery rates in West Africa [27]. Additionally, 
14.5% (743/5134) of patients with suspected meningitis in 
Nigeria received antibiotics before admission, which may have 
contributed to low bacteriological recovery. Moreover, without 
the sophisticated laboratory techniques used, diagnosis of bac-
terial meningitis would have relied on clinical characteristics. 
Thus, the 44 (28.8%: 44/153) PBM patients presenting with 
clear CSF and low WBC count may have been misdiagnosed. 
A history of fever (84.3%: 129 /153) and presence of seizures 
(71.2%: 109/153) were the most common symptoms associated 
with confirmed PBM cases in Nigeria. However, an altered con-
sciousness is a more accurate indicator of bacterial meningitis 
when combined with other common symptoms [28]. During 
surveillance, only 22% (34/153) of meningitis patients had 
an altered consciousness. Additionally, meningismus (10.5%: 
16/153) and bulging fontanelle (8.5%: 13/153) were observed 
less frequently, highlighting the importance of considering all 
clinical symptoms when diagnosing PBM as outlined in the 
WHO guidelines [16].
West Africa has a bimodal climate: wet season occurs from 
mid-April until mid-October, and the remaining months are 
characterized by dry season. Available data suggest the inten-
sity of bacterial meningitis epidemics are associated with the 
Harmattan winds during dry season; thus, epidemics are rare 
during rainy season [29, 30]. The seasonal distribution of PBM 
within Nigeria from 2010 to 2016 is in line with this trend 
(Figure 3). Previous studies have shown that respiratory syn-
cytial virus (RSV) is also seasonal in Nigeria, with cases mainly 
observed during the dry season and often peaking in November 
[31, 32]. Conversely, influenza has been shown to have year-
round activity within Nigeria [33, 34]. Moreover, the season-
ality of malaria transmission within Nigeria differs across the 
country based on the various ecological regions. Thus, malaria 
transmission is often year-round in southern Nigeria where 
there are high levels of mangrove swamps but lasts 3 months 
or less in northern regions such as the Sahel-savannah [35, 36].
Vaccines targeting the main bacterial pathogens causing 
meningitis are effective at reducing morbidity and mortality 
[37, 38]. The Hib vaccine was introduced in phases across 
Nigeria from May 2012 to May 2014, and 41.4% (12/29) of the 
H. influenzae associated meningitis cases occurred during this 
period, with a further 48.3% (14/29) cases postvaccine intro-
duction. We identified 11 cases of Hib meningitis; of these, 7 
patients had not received the Hib vaccine, and the Hib vacci-
nation status for the remaining 4 patients was unknown. The 
WHO and UNICEF 2017 national immunization coverage 
estimates for the Hib containing vaccine in Nigeria were <50% 
[15]. Additionally, in 2017, Nigeria’s National Primary Health 
Care Development Agency (NPHCDA) found that only Bauchi 
and Kwara of the 5 states participating in PBM surveillance re-
ported >50% coverage of the Hib vaccine, indicating that cov-
erage across Nigeria needs to be improved [39].
MenAfriVac against serogroup A  has not been introduced 
into routine immunization programs in Nigeria but was given 
to at risk populations during mass campaigns from 2011 to 2014 
in high-risk states. Therefore, the recording of MenAfriVac vac-
cination status of patients during surveillance was limited, with 
4 patients reporting they had received the vaccines, 650 patients 
reporting they had not, and 4480 patients where this informa-
tion was unknown or not recorded. However, of the 20 isolates 
we serogrouped, none were serogroup A; instead, serogroup W 
was the predominant strain, followed by nongroupable strains. 
Expansion of nonvaccine serogroups due to vaccine selection 
pressures could be responsible for the increased incidence of 
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nonserogroup A meningococcus, but, as limited serogrouping 
data were obtained, further work is required to conclude sero-
type replacement is occurring [40].
Pneumococcus was the predominant pathogen causing 71 
(46.4%: 71/153) PBM cases during surveillance in Nigeria. 
A high incidence of pneumococcal meningitis is also common 
in The Gambia [25]. Of the 5 states where surveillance occurred, 
Edo state commenced PCV10 vaccinations in 2014, and only 2 
pneumococcal meningitis cases were reported here afterward. 
The remaining 4 states received PCV10 in 2016; thus, pre- and 
postvaccine comparisons are not possible, and we were unable 
to record the PCV10 vaccination status of patients throughout 
our surveillance period. However, 46.4% (13/28) of the isolates 
serotyped were strains that are included in PCV10 and thus 
could have been prevented by immunization. The 2017 WHO 
and UNICEF national immunization coverage estimates sug-
gest that coverage rates for PCV10 are <50% in Nigeria [15]. For 
each of the 5 states enrolled in surveillance, coverage of 3 PCV10 
doses from January to November 2017 was >50% in Bauchi and 
Kwara only [39]. We found 1 case of pneumococcal meningitis 
caused by serotype 19A, targeted by PCV13 but not PCV10, 
and 13 cases caused by pneumococcal serotypes that were 
nontypeable and thus not covered by current PCV formulations. 
Serotype replacement of vaccine serotypes with nonvaccine 
serotypes is a phenomenon that has been widely reported since 
the introduction of PCVs [41, 42]. However, due to the limited 
pneumococcal serotype data reported and the recent introduc-
tion of PCV10, surveillance should be continued in Nigeria to 
monitor the burden of vaccine preventable bacterial meningitis 
and any potential changes in serotype distribution over time.
Limitations
During this surveillance, children with suspected meningitis were 
not followed up after hospital discharge. There were a total of 278 
(5.4%: 278/5134) in-hospital deaths; of these, 23 (8.2%: 23/278) 
were patients with confirmed bacterial meningitis. However, the 
outcome for 1749 patients (34.1% 1749/5134) was unknown or 
not recorded, and of these, 26 (1.5%: 26/1749) were patients with 
confirmed bacterial meningitis. Therefore, the case fatality of 
5.4% (278/5134) among children with suspected meningitis may 
have been higher, but this cannot be confirmed. Additionally, 102 
(2%: 102/5134) patients were reported to have long-term sequelae; 
however, 3245 (63.2%: 3245/5134) were not followed up after dis-
charge, and the HIV status was not routinely recorded during 
the surveillance. Moreover, there were discrepancies between the 
level of reporting from each sentinel hospital. In future studies, 
it would be beneficial to record information regarding long-term 
sequelae, outcome at discharge, and HIV status for all patients 
with suspected meningitis and to do this in a standardized manner 
across all sites. This would allow more accurate rates of morbidity 
and mortality associated with bacterial meningitis within the sur-
veillance populations to be estimated.
CONCLUSIONS
Pneumococcus was responsible for the majority of PBM cases 
in Nigeria; however, PCV10 has now been introduced within 
all states included in surveillance, and with improved vaccine 
coverage it is expected that pneumococcal meningitis rates will 
start to decline. Hib remains responsible for a significant pro-
portion of meningitis despite vaccine introduction. Therefore, 
our findings emphasize the need for further monitoring to es-
tablish the impact of conjugate vaccines on reducing the preva-
lence of bacterial meningitis within Nigeria. Further serotype/
group data for PBM cases is required to understand the distri-
bution of specific pathogen strains across Nigeria and to en-
hance efficacy of target vaccines.
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